BioSpace News Archive

The PumasAI Board of Directors are pleased to announce that, effective January 1, 2024, Dr. Vijay Ivaturi will be stepping into the role of Chief Executive Officer, succeeding Dr. Joga Gobburu. After four years of dedicated leadership, Dr. Gobburu will be transitioning from his current role as CEO to the position of Chairman of the Board of PumasAI.

Synplogen Co., a synthetic biology startup spun out of Kobe University’s Graduate School of Science, Technology and Innovation that provides custom DNA synthesis and Gene Therapy Biofoundry services, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a non-binding Memorandum of Understanding (“MOU”).

Contract Medical and Commercial Organization, Amplity Health has released a revolutionary AI-driven next best action solution that provides pharmaceutical and biopharmaceutical companies with an entirely new order of field insights that can be acted upon within the earliest days of a drug’s release.

Exai Bio today announced new data demonstrating that its novel RNA-based and AI-driven liquid biopsy platform can detect breast cancer at the earliest stages and the smallest tumor sizes, including ductal carcinoma in situ (DCIS), using a standard blood sample.

ZyVersa Therapeutics, Inc. announced the pricing of a “reasonable best efforts” public offering of 4,000,000 shares of common stock and accompanying Series A and Series B warrants to purchase up to an aggregate of 8,000,000 shares of common stock at a combined public offering price of $1.25, resulting in gross proceeds of approximately $5.0 million.

BIOLASE, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $1.4 million of its common stock and pre-funded warrants in a registered direct offering and warrants to purchase common stock in a concurrent private placement, priced at-the-market under Nasdaq rules.

MEDSIR today announced the results from the PARSIFAL-LONG study, a 5-year extended follow-up of the PARSIFAL study on endocrine-sensitive hormone receptor-positive/HER2-negative advanced breast cancer, demonstrating the effectiveness of two combined option therapies (palbociclib-letrozole and palbociclib-fulvestrant) as first-line treatments for metastatic breast cancer.

Compass Pathways plc announced the publication of a paper in JAMA Psychiatry that demonstrates the potential for investigational COMP360 psilocybin treatment in treatment-resistant bipolar type II disorder.

Treadwell Therapeutics today announced that it is realigning its pipeline, workforce and management structure to support its highest value program and extend its cash runway to prioritize the execution of key near term value drivers and clinical milestones.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host its Investor and Analyst Day on Tuesday, December 12, 2023.